ZTEK zentek.com: Company Value to Revenue

Official company branding of Zentek (ZTEK)

A stable Canadian base and the absence of sanction risks provide Zentek Ltd. (ZTEK) with a reliable operational backdrop. The enterprise value-to-revenue multiple clearly demonstrates the valuation trend, with the parameter stabilizing at 649500.00. Leadership in the development of antibacterial nanofilters complements a closed patent strategy, where graphene coatings ensure high B2B customer loyalty.

zentek.com (ZTEK): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 09/12/2026

ZTEK (Zentek Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
- cash balance and cash flow data:
Fundamental valuation:Zentek Ltd.
Manufactured products of Zentek Limited

Zentek Ltd. is scaling the commercialization of graphene nanomaterials for medicine and ecology while remaining in a stage of active technological growth. This enterprise value-to-revenue (EV/Revenue) valuation compares the total value of the business with sales volume, excluding the impact of leverage, which allows investors to assess the efficiency of patent monetization and the sustainability of capitalization in an environment of expensive debt capital.

Competitor analysis for Zentek Ltd.

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|Microbot Medical Inc - Company Value to Revenue|Total Company Value-to-Revenue Ratio Pro-Dex Inc. (PDEX)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple